Real-world treatment patterns before and after receiving PD-L1 test results in patients (pts) with advanced non-small cell lung cancer (aNSCLC)

被引：0
|
作者：
Antonia, S. J. [1 ]
Wu, N. [2 ]
Ge, W. [2 ]
Pouliot, J-F. [2 ]
Dietz, H. [1 ]
Jalbert, J. [2 ]
Quek, R. G. [2 ]
Harnett, J. [2 ]
机构：
[1] Duke Univ, Ctr Canc Immunotherapy, Sch Med, Durham, NC USA
[2] Regeneron Pharmaceut Inc, Tarrytown, NY USA
来源：
ANNALS OF ONCOLOGY | 2021年 / 32卷
关键词：
D O I：
10.1016/j.annonc.2021.10.121
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
103P
引用
收藏
页码：S1419 / S1420
页数：2
相关论文
共 50 条
  • [41] First-line (1L) osimertinib in EGFR mutant (mut) advanced non-small cell lung cancer (aNSCLC) patients (pts): Progression (PD) pattern and safety in the real-world (RW)
    Lorenzi, M.
    Dal Maso, A.
    Ferro, A.
    Polo, V.
    Scattolin, D.
    Macerelli, M.
    Follador, A.
    Targato, G.
    Indraccolo, S.
    Frega, S.
    Menis, J.
    Bonanno, L.
    Guarneri, V.
    Conte, P. F.
    Pasello, G.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (04) : S779 - S779
  • [42] Real-world study of PD-L1 testing patterns and treatment distribution in patients with metastatic non-small-cell lung cancer in Israel
    Moser, Sarah Sharman
    Apter, Lior
    Arunachalam, Ashwini
    Burke, Thomas
    Shalev, Varda
    Chodick, Gabriel
    Siegelmann-Danieli, Nava
    IMMUNOTHERAPY, 2021, 13 (10) : 851 - 861
  • [43] Real-World Treatment Patterns Among Resected Patients With Non-Small Cell Lung Cancer Receiving Adjuvant Atezolizumab
    Lee, Jay M.
    Ogale, Sarika
    Johnson, Ann
    Patel, Achal
    Albarmawi, Husam
    Lee, Janet S.
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (07) : E43 - E43
  • [44] Real-World PD-(L)1 Inhibitor Treatment Pattern and Outcomes in Advanced Non-Small Cell Lung Cancer in Sweden
    Wagenius, G.
    Vikstrom, A.
    Berglund, A.
    Salomonsson, S.
    Bencina, G.
    Hu, X.
    Chirovsky, D.
    Brunnstrom, H.
    Ekman, S.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S380 - S381
  • [45] Real-world outcomes of patients with advanced non-small cell lung cancer (aNSCLC) and autoimmune disease (AD) receiving immune checkpoint inhibitors (ICIs).
    Khozin, Sean
    Walker, Mark S.
    Jun, Monika
    Chen, Li
    Stepanski, Edward
    Rubinstein, Wendy S.
    Komatsoulis, George Anthony
    Roberts, Jeremy
    Zhi, Jizu
    Miller, Robert S.
    Fukushima, Ryan
    Lau, Denise
    Hyde, Brigham
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [46] PD-L1 expression for advanced non-small cell lung cancer patients with cancer cachexia
    Morimoto, Kenji
    Yamada, Tadaaki
    CANCER SCIENCE, 2023, 114 : 1410 - 1410
  • [47] COSTS OF CARE FOR FIRST-LINE (1L) TREATMENT OF ADVANCED NON-SMALL CELL LUNG CANCER (ANSCLC): A REAL-WORLD CLAIMS ANALYSIS
    Kish, Jonathan
    Chopra, Dhruv
    Liassou, Djibril
    Lubinga, Solomon
    Hartman, John
    Feinberg, Bruce
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A437 - A438
  • [48] Real-world evidence and clinical observations of the treatment of advanced non-small cell lung cancer with PD-1/PD-L1 inhibitors (vol 9, 4278, 2019)
    Song, Peng
    Zhang, Jingcheng
    Shang, Congcong
    Zhang, Li
    SCIENTIFIC REPORTS, 2020, 10 (01)
  • [49] Contemporary management of advanced non-small cell lung cancer aNSCLC) in a large, real-world cohort.
    Presley, Carolyn Jean
    Harrington, Eoghan
    Gippetti, James
    Agarwala, Vineeta
    Bowser, Bryan
    Adelson, Kerin B.
    Herbst, Roy S.
    Abernethy, Amy Pickar
    Gross, Cary Philip
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [50] Real-world prospective data of small biopsy samples for tumor PD-L1 expression in non-small cell lung cancer
    Morikawa, K.
    Tsunoda, A.
    Inoue, T.
    Mineshita, M.
    ANNALS OF ONCOLOGY, 2018, 29
12345